Gland Pharma (GLAND) Stock Overview
Engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for GLAND from our risk checks.
GLAND Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gland Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,221.80 |
| 52 Week High | ₹2,295.10 |
| 52 Week Low | ₹1,456.20 |
| Beta | 0.38 |
| 1 Month Change | 23.80% |
| 3 Month Change | 20.72% |
| 1 Year Change | 41.40% |
| 3 Year Change | 137.77% |
| 5 Year Change | -31.82% |
| Change since IPO | 22.11% |
Recent News & Updates
Analysis Article • May 19
Gland Pharma Limited Just Recorded A 8.8% EPS Beat: Here's What Analysts Are Forecasting Next
A week ago, Gland Pharma Limited ( NSE:GLAND ) came out with a strong set of full-year numbers that could potentially...
Narrative Update • May 15
GLAND: Leadership Change Will Limit Benefits From New US FDA Approvals
Analysts have raised their fair value estimate for Gland Pharma to ₹1,575 from ₹1,525, reflecting updated views on revenue growth, profit margins and future P/E expectations. What's in the News U.S. FDA approved an Abbreviated New Drug Application for generic Infuvite Pediatric Injection, with eligibility for 180-day Competitive Generic Therapy exclusivity on the single dose vial, where Gland Pharma contributed sterile injectable manufacturing capabilities alongside Apotex and Orbicular (Product related announcement).Recent updates
Analysis Article • May 19
Gland Pharma Limited Just Recorded A 8.8% EPS Beat: Here's What Analysts Are Forecasting Next
A week ago, Gland Pharma Limited ( NSE:GLAND ) came out with a strong set of full-year numbers that could potentially...Narrative Update • May 15
GLAND: Leadership Change Will Limit Benefits From New US FDA Approvals
Analysts have raised their fair value estimate for Gland Pharma to ₹1,575 from ₹1,525, reflecting updated views on revenue growth, profit margins and future P/E expectations. What's in the News U.S. FDA approved an Abbreviated New Drug Application for generic Infuvite Pediatric Injection, with eligibility for 180-day Competitive Generic Therapy exclusivity on the single dose vial, where Gland Pharma contributed sterile injectable manufacturing capabilities alongside Apotex and Orbicular (Product related announcement).
Narrative Update • Apr 30
GLAND: Future US Approvals For Pediatric And Eye Drugs Will Drive Rerating
Analysts keep their price target for Gland Pharma steady at ₹2,500, reflecting slightly higher assumptions for revenue growth and profit margin, along with a marginally lower future P/E multiple in their refreshed model. What's in the News Apotex, Orbicular and Gland Pharma received U.S. FDA approval for a generic Infuvite Pediatric Injection ANDA, with eligibility for 180-day Competitive Generic Therapy exclusivity for the single dose vial, with Apotex leading U.S. commercialization (Product-Related Announcement).Narrative Update • Apr 16
GLAND: Pipeline Approvals And Leadership Changes Will Constrain Future Share Returns
Analysts have trimmed their price target on Gland Pharma from ₹1,555 to ₹1,525, citing updated assumptions that balance a lower revenue growth outlook with higher profit margin expectations and a more conservative future P/E multiple. What's in the News Apotex Corp., Orbicular Pharmaceutical Technologies and Gland Pharma received U.S. FDA approval for two ANDAs for generic Infuvite Adult Injection, including 180-day Competitive Generic Therapy exclusivity for the pharmacy bulk package, with Gland providing sterile injectable manufacturing support (Key Developments).Narrative Update • Apr 01
GLAND: Future US Approvals For Eye And Oncology Drugs Will Drive Rerating
Analysts have maintained Gland Pharma's fair value estimate at ₹2,500, citing updated assumptions around a slightly lower discount rate, revised revenue growth expectations, adjusted profit margin inputs, and a refreshed future P/E multiple as the basis for the unchanged price target. What's in the News Received tentative USFDA approval for Brimonidine Tartrate Ophthalmic Solution 0.025% (OTC), a generic version of Lumify Ophthalmic Solution 0.025%, indicated to relieve eye redness, with reference product US sales of about US$39 million for the twelve months ending September 2025 (IQVIA).
Narrative Update • Mar 18
GLAND: Future Returns Will Be Driven By Stable Margins And USFDA Approvals
Analysts leave their fair value estimate for Gland Pharma unchanged at ₹1,964, citing broadly consistent assumptions on revenue growth, profit margins, discount rate and forward P/E. Together these factors support a stable price target outlook for now.Narrative Update • Mar 04
GLAND: Future Returns Will Be Guided By Margin Strength And Regulatory Approvals
Analysts now place Gland Pharma's price target at ₹1,964, slightly below the prior ₹1,970. The revision reflects updated assumptions around revenue growth, profit margin, and a modestly lower future P/E multiple.Narrative Update • Feb 18
GLAND: Future Returns Will Be Shaped By Margin Resilience And Regulatory Progress
Analysts have trimmed their price target for Gland Pharma from ₹1,989.50 to ₹1,969.54, reflecting updated assumptions around slightly lower revenue growth, a modestly higher profit margin, a reduced future P/E multiple, and a small adjustment to the discount rate. What's in the News USFDA approval for Zoledronic Acid Injection, 4 mg/100 mL single dose bags, a generic version of Zoledronic Acid Injection indicated for treating hypercalcemia of malignancy, multiple myeloma, and bone metastases of solid tumors, with US sales of about US$6.7m for the twelve months ending November 2025 according to IQVIA (company announcement, IQVIA) USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), a generic equivalent to Pataday Once Daily Relief 0.7% for treating ocular itching linked to allergic conjunctivitis (company announcement) Board meeting scheduled on January 28, 2026, at 15:00 IST to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider reappointment of Grant Thornton Bharat LLP as internal auditors (company filing) Valuation Changes Fair Value: revised slightly lower from ₹1,989.50 to ₹1,969.54.Narrative Update • Feb 03
GLAND: Future USFDA Approvals Will Support A Higher Market Rerating
Analysts have adjusted their price target for Gland Pharma from ₹2,340 to ₹2,500. This change reflects updated assumptions on discount rate, revenue growth, profit margins and the P/E multiple they apply to the business.Analysis Article • Jan 31
Gland Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Gland Pharma Limited ( NSE:GLAND ) came out with a strong set of quarterly numbers that could potentially...Narrative Update • Jan 20
GLAND: Future Returns Will Balance Product Pipeline Progress With Lower Valuation Multiple
Analysts have reduced their fair value estimate for Gland Pharma from ₹1,680 to ₹1,555, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Board meeting scheduled on January 28, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative Update • Jan 06
GLAND: Future Returns Will Be Driven By Stable Margins And Board Results Update
Analysts have trimmed their price target for Gland Pharma slightly to ₹1,989.50 from ₹2,007.83, reflecting updated fair value estimates while keeping key assumptions such as discount rate, revenue growth, profit margin, and future P/E broadly unchanged. What's in the News Board meeting scheduled for November 3, 2025 at 15:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Narrative Update • Dec 22
GLAND: Future Performance Will Balance Higher Multiple With Moderating Margins
Analysts have raised their price target on Gland Pharma from ₹1,220 to ₹1,680, reflecting higher valuation multiples despite moderating expectations for revenue growth and profit margins. What's in the News Board meeting scheduled on November 3, 2025, at 15:00 IST to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Management to release a press note alongside the results, outlining key performance highlights and strategic updates for the reporting period (company filing) An investor presentation will be issued in conjunction with the results, providing additional detail on financial performance and business outlook (company filing) Valuation Changes Fair Value Estimate was raised significantly from ₹1,219.79 to ₹1,680.00, implying a materially higher intrinsic valuation.Narrative Update • Dec 08
GLAND: Future Earnings Will Be Driven By Stable Margins And US Regulatory Milestones
Analysts have maintained their price target on Gland Pharma at ₹2,007.83 per share, reflecting unchanged assumptions on revenue growth, profit margins, and future valuation multiples despite the latest review of the company’s fundamentals. What's in the News A board meeting is scheduled on November 3, 2025 at 15:00 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Narrative Update • Nov 24
GLAND: Future Earnings Will Be Driven By US Regulatory Milestones
Analysts have raised their price target for Gland Pharma from ₹1,925 to approximately ₹2,008, reflecting updated forecasts for valuation multiples as well as expected company performance. What's in the News The Board of Directors will meet on November 3, 2025 at 15:00 IST to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025.Narrative Update • Nov 08
GLAND: Revenue Opportunities And Competitive Risks Will Be Balanced Going Forward
Narrative Update: Gland Pharma Price Target Revision Analysts have slightly lowered their price target for Gland Pharma from ₹1,938 to ₹1,925. This reflects modestly tempered expectations on revenue growth, profitability, and valuation multiples.Analysis Article • Nov 08
Is Gland Pharma (NSE:GLAND) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrative Update • Oct 25
Upcoming Drug Approvals and Market Exclusivity Will Drive Future Opportunity
Analysts have marginally raised their price target for Gland Pharma from ₹1,933.64 to ₹1,938.18. The adjustments reflect slight updates in growth and profitability expectations.Narrative Update • Oct 11
Expanded Manufacturing Capacity Will Unleash Market Opportunity
Analysts have raised their price target for Gland Pharma from ₹1,862.83 to ₹1,933.64, citing a modest improvement in fair value estimates and expectations for future earnings. What's in the News Gland Pharma received USFDA approval for Vasopressin in 5% Dextrose Injection, both 40 Units and 20 Units per 100 mL RTU Vials.Analysis Article • Sep 15
Gland Pharma Limited's (NSE:GLAND) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 43.2x Gland Pharma Limited ( NSE:GLAND ) may be sending very bearish...Narrative Update • Sep 05
Expanded Manufacturing Capacity Will Unleash Market Opportunity
With consensus forecasts for both future P/E (25.87x) and annual revenue growth (14.5%) unchanged, analysts have maintained Gland Pharma’s fair value at ₹1863. What's in the News Gland Pharma received USFDA approval for Vasopressin in 5% Dextrose Injection (40 Units/100 mL); tentative approval granted for 20 Units/100 mL variant, targeting a $45 million US market.Analysis Article • Aug 08
Here's What Analysts Are Forecasting For Gland Pharma Limited (NSE:GLAND) After Its First-Quarter Results
NSEI:GLAND 1 Year Share Price vs Fair Value Explore Gland Pharma's Fair Values from the Community and select yours...Analysis Article • Aug 05
Gland Pharma's (NSE:GLAND) Dividend Is Being Reduced To ₹18.00
Gland Pharma Limited ( NSE:GLAND ) has announced that on 28th of September, it will be paying a dividend of₹18.00...Analysis Article • Jul 17
Is Gland Pharma (NSE:GLAND) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • May 23
Gland Pharma Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Investors in Gland Pharma Limited ( NSE:GLAND ) had a good week, as its shares rose 5.9% to close at ₹1,547 following...Analysis Article • Apr 09
The Price Is Right For Gland Pharma Limited (NSE:GLAND)
Gland Pharma Limited's ( NSE:GLAND ) price-to-earnings (or "P/E") ratio of 33.3x might make it look like a sell right...Analysis Article • Feb 06
Results: Gland Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
The quarterly results for Gland Pharma Limited ( NSE:GLAND ) were released last week, making it a good time to revisit...Analysis Article • Jan 26
Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Narrative • Dec 24
New Ampoule Line At Cenexi And Dr Reddy's Biologics Collaboration To Propel Revenue Growth And Enhance Earnings
New high-capacity ampoule line and leadership changes are expected to increase manufacturing capacity, customer service, and strategic execution, boosting revenue and margins.Analysis Article • Nov 07
Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next
Gland Pharma Limited ( NSE:GLAND ) just released its latest second-quarter report and things are not looking great...Analysis Article • Oct 26
Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate
Key Insights Gland Pharma's estimated fair value is ₹1,304 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Oct 01
Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Sep 05
Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)
With a price-to-earnings (or "P/E") ratio of 43.1x Gland Pharma Limited ( NSE:GLAND ) may be sending bearish signals at...Analysis Article • Aug 09
Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
As you might know, Gland Pharma Limited ( NSE:GLAND ) last week released its latest quarterly, and things did not turn...Analysis Article • Jun 22
Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • May 25
Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts
It's been a good week for Gland Pharma Limited ( NSE:GLAND ) shareholders, because the company has just released its...Analysis Article • Mar 19
Is Gland Pharma (NSE:GLAND) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 16
Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 31x, you may consider Gland...Shareholder Returns
| GLAND | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 20.5% | 3.7% | 0.5% |
| 1Y | 41.4% | 10.5% | -0.7% |
Return vs Industry: GLAND exceeded the Indian Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: GLAND exceeded the Indian Market which returned -0.3% over the past year.
Price Volatility
| GLAND volatility | |
|---|---|
| GLAND Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: GLAND has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: GLAND's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 4,351 | n/a | www.glandpharma.com |
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients.
Gland Pharma Limited Fundamentals Summary
| GLAND fundamental statistics | |
|---|---|
| Market cap | ₹366.06b |
| Earnings (TTM) | ₹10.27b |
| Revenue (TTM) | ₹64.31b |
35.6x
P/E Ratio5.7x
P/S RatioIs GLAND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAND income statement (TTM) | |
|---|---|
| Revenue | ₹64.31b |
| Cost of Revenue | ₹24.46b |
| Gross Profit | ₹39.85b |
| Other Expenses | ₹29.58b |
| Earnings | ₹10.27b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 62.35 |
| Gross Margin | 61.97% |
| Net Profit Margin | 15.98% |
| Debt/Equity Ratio | 2.3% |
How did GLAND perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield32%
Payout RatioDoes GLAND pay a reliable dividends?
See GLAND dividend history and benchmarks| Gland Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Aug 11 2026 |
| Dividend Pay Date | Sep 24 2026 |
| Days until Ex dividend | 82 days |
| Days until Dividend pay date | 126 days |
Does GLAND pay a reliable dividends?
See GLAND dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 02:20 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gland Pharma Limited is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Nithya Balasubramanian | Bernstein |